Tagged with Hong Kong

Asia-Pacific Andrew Hexter, VP and GM of Gilead Asia 5 (Hong Kong, Singapore, South Korea, Taiwan and Malaysia), shares the highlights of his past three years leading the diverse region, the significance of Asian markets being the first to approve remdesivir as a COVID-19 treatment, and the importance of public-private partnerships…

Hong Kong It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain criteria. In May 2020, during the first in a series of webinars organized by the HKEX to celebrate the second…

Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…

Precision Medicine With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region must be addressed effectively, quickly and comprehensively. Who better to accomplish that than the Asian companies on the ground, closest…

Hong Kong Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong sheds light on the Asian diagnostics market and unveils his strategy to expand Xcelom’s offering across Asia.   Our pursuit…

Hong Kong Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning within health technology is shifting, and why more and more biotech firms are choosing to IPO in Hong Kong.  …

Hong Kong Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative drug development in China, and the challenges of establishing a biotech company in Hong Kong.   Our research within AI…

Hong Kong Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy to develop their brand in South East Asia, the changes he foresees for the industry post the COVID-19 pandemic, and…

Hong Kong Kelvin Chiu and Isabelle Dutry of Sanwa BioTech in Hong Kong highlight the critical importance of personalised fast-track diagnostics in countering the COVID-19 pandemic, the role that Asian firms have to play in remedying the global shortage of medical supplies, and what the future holds for Sanwa.   Looking at…

Hong Kong Michael Chan, Senior Vice President of Global Issuer Services for the Hong Kong Exchange (HKEX) highlights the vibrancy and diversity that biotechs have brought to the market, HKEX’s three unique advantages, and how the Hong Kong market aims to adapt to greater demands for diversity.    Hong Kong has a…

China PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their successful HKEX IPO in December 2019, his commercial expectations for their flagship PD-1/PD-L1 product, and the impact of COVID-19 on their operations.   The core business…

China 2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland China, listing last year. The average amount of funds raised by these was a whopping four to five times higher…